- severe liver dysfunction (child pugh ≥ 3 or ast> 5 times normal) - severe renal dysfunction with glomerular filtration <30 ml / minute or under treatment with hemodialysis or peritoneal dialysis. - poorly controlled hypertension (bps> 160 mmhg or tad <100 mmhg) or having a history previous hypertensive crisis or hypertensive encephalopathy. - history of poorly controlled heart disease with a nyha> 2. - history of thrombosis in the previous 6 months. - signs of active bleeding. - open wounds, gastrointestinal perforation. - diagnosis of thrombophilic diseases or hemorrhagic diathesis. - active viral hepatitis or hiv not properly treated. - intolerance or allergy to bevacizumab or its components. - pregnancy.

- severe liver dysfunction (child pugh ≥ 3 or ast> 5 times normal) - severe renal dysfunction with glomerular filtration <30 ml / minute or under treatment with hemodialysis or peritoneal dialysis. - poorly controlled hypertension (bps> 160 mmhg or tad <100 mmhg) or having a history previous hypertensive crisis or hypertensive encephalopathy. - history of poorly controlled heart disease with a nyha> 2. - history of thrombosis in the previous 6 months. - signs of active bleeding. - open wounds, gastrointestinal perforation. - diagnosis of thrombophilic diseases or hemorrhagic diathesis. - active viral hepatitis or hiv not properly treated. - intolerance or allergy to bevacizumab or its components. - pregnancy.